Starfighters Space Borrow Rate Increases to 282.66%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3d ago
0mins
Latest data shows the largest indicative borrow rate increases among liquid option names include: Starfighters Space, Inc. (FJET) 282.66% +4.55, PureCycle Technologies (PCT) 7.61% +1.46, Infosys (INFY) 10.84% +1.06, Defiance 1.75x MSTR ETF (MSTX) 25.48% +0.42, Guggenheim Global Solar Index (TAN) 10.29% +0.37, - Abivax SA American Depositary Shares (ABVX) 0.66% +0.20, Direxion Daily Regional Banks Bull 3X Shares (DPST) 1.05% +0.18, Gilead (GILD) 0.42% +0.17, iShares DJ US Home Construction Index Fund (ITB) 2.71% +0.16, and Novo Nordisk (NVO) 0.41% +0.16.
Analyst Views on ABVX
Wall Street analysts forecast ABVX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABVX is 129.25 USD with a low forecast of 101.00 USD and a high forecast of 176.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 125.010
Low
101.00
Averages
129.25
High
176.00
Current: 125.010
Low
101.00
Averages
129.25
High
176.00
About ABVX
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.





